Opus Genetics Statistics
Total Valuation
Opus Genetics has a market cap or net worth of $30.81 million. The enterprise value is -$5.83 million.
| Market Cap | 30.81M |
| Enterprise Value | -5.83M |
Important Dates
The last earnings date was Tuesday, November 12, 2024, before market open.
| Earnings Date | Nov 12, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Opus Genetics has 31.44 million shares outstanding. The number of shares has increased by 13.36% in one year.
| Current Share Class | 31.44M |
| Shares Outstanding | 31.44M |
| Shares Change (YoY) | +13.36% |
| Shares Change (QoQ) | +1.23% |
| Owned by Insiders (%) | 5.54% |
| Owned by Institutions (%) | 8.14% |
| Float | 27.13M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.91 |
| Forward PS | n/a |
| PB Ratio | 0.75 |
| P/TBV Ratio | 0.90 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.63
| Current Ratio | 6.63 |
| Quick Ratio | 6.56 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -22.19 |
Financial Efficiency
Return on equity (ROE) is -64.30% and return on invested capital (ROIC) is -43.56%.
| Return on Equity (ROE) | -64.30% |
| Return on Assets (ROA) | -38.95% |
| Return on Capital (ROIC) | -43.56% |
| Revenue Per Employee | $598,643 |
| Profits Per Employee | -$1.94M |
| Employee Count | 14 |
| Asset Turnover | 0.18 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -2,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -66.55% in the last 52 weeks. The beta is 0.32, so Opus Genetics's price volatility has been lower than the market average.
| Beta (5Y) | 0.32 |
| 52-Week Price Change | -66.55% |
| 50-Day Moving Average | 1.23 |
| 200-Day Moving Average | 1.68 |
| Relative Strength Index (RSI) | 37.54 |
| Average Volume (20 Days) | 195,398 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Opus Genetics had revenue of $8.38 million and -$27.19 million in losses. Loss per share was -$1.09.
| Revenue | 8.38M |
| Gross Profit | -15.39M |
| Operating Income | -29.47M |
| Pretax Income | n/a |
| Net Income | -27.19M |
| EBITDA | -29.47M |
| EBIT | -29.47M |
| Loss Per Share | -$1.09 |
Balance Sheet
| Cash & Cash Equivalents | 36.64M |
| Total Debt | n/a |
| Net Cash | 36.64M |
| Net Cash Per Share | $1.17 |
| Equity (Book Value) | 34.30M |
| Book Value Per Share | 1.31 |
| Working Capital | 34.30M |
Cash Flow
| Operating Cash Flow | -13.59M |
| Capital Expenditures | n/a |
| Free Cash Flow | -13.59M |
| FCF Per Share | -$0.43 |
Margins
| Gross Margin | -183.63% |
| Operating Margin | -351.68% |
| Pretax Margin | -324.47% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Opus Genetics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -13.36% |
| Shareholder Yield | -13.36% |
| Earnings Yield | -88.27% |
| FCF Yield | -44.11% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Opus Genetics has an Altman Z-Score of 0.37 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.37 |
| Piotroski F-Score | 1 |